BMSN. Benitec Announces Acquisition of Tacere

New Post Public Reply Private Reply Replies (0) Message Board
Stephen218
BMSN. Benitec Announces Acquisition of Tacere Therapeutics and Phase I/II Ready Hepatitis C (HCV) Program

SYDNEY, AUSTRALIA and SAN JOSE, CA -- (Marketwire) -- 10/11/12 -- Benitec Biopharma (ASX: BLT)

Key points:

Acquisition of US-based Tacere Therapeutics brings Phase I/II ready clinical development program in Hepatitis C (HCV)
Highly compatible technology based on Benitec Biopharma's novel ddRNAi-based gene silencing technology
Attractive commercial terms attained, based on Tacere's original licensing of Benitec's ddRNAi technology
Complements and expands Benitec Biopharma's clinical development pipeline by adding high value HCV program with solid preclinical data and extensive safety profile
Benitec Biopharma (ASX: BLT) today announced the acquisition of US-based RNA interference (RNAi) therapeutics company Tacere Therapeutics, Inc. (Tacere). Tacere is a privately-held drug development company with a Phase I/II ready program in hepatitis C (HCV) that utilises Benitec Biopharma's novel gene silencing technology called DNA-directed RNA interference (ddRNAi).

Benitec Biopharma will acquire Tacere's extensive HCV program data and materials, as well as an advanced preclinical program for the eye disease macular degeneration, which also utilises the Company's ddRNAi technology.

The closing consideration for the acquisition will be non-cash in the form of an issue of 102,321,345 new shares in Benitec Biopharma for just under USD 1.5 million, plus a potential cash royalty on future licensing revenue received calculated as follows: 35% if the licence is entered into prior to commencement of a Phase II clinical study; or 15% prior to commencement of a Phase III clinical study; or 5% if prior to the submission of a Biologic License Application to the US Food and Drug Administration or 2.5% if after Biologic License Application submission.

The new shares will represent 9.5% of the issued capital and will be fully paid ordinary shares ranking equally with existing listed shares. The share issue will be made within Benitec Biopharma's 15% annual placement capacity under ASX Listing Rule 7.1 and will not require shareholder approval. Subject to any requirements imposed by the ASX, the vendors have voluntarily agreed that 75% of the shares issuable in the transaction will be held subject to escrow for 12 months. Completion of the of the acquisition is expected within the next two weeks and is subject to standard closing conditions, including execution of certain ancillary agreements.

As part of the acquisition Tacere's Chief Scientist Officer, Dr. David Suhy, will be joining Benitec Biopharma in the new role of Vice President Research & Development.

"We are delighted to announce the acquisition of Tacere and its lead compound TT-034 for HCV," said Dr. Peter French, CEO of Benitec Biopharma. "Tacere has been successfully developing programs utilising Benitec's proprietary ddRNAi technology since 2006, and it now makes sense to bring these assets in-house to complement and strengthen our pipeline as we move into clinical development. We believe the preclinical data and safety profile of TT-034 positions the Company to commence clinical trials in hepatitis C at a time when a number of high profile HCV therapies such as nucleotide polymerase inhibitor are encountering safety concerns. The Tacere program provides us with the opportunity to commence Phase I/II clinical trials in mid-2013."

Further details on the Tacere acquisition and programs are available in the presentation lodged with this announcement. An interview with Benitec Biopharma's CEO Dr. Peter French and Tacere's Director of R&D Dr. David Suhy addressing key questions regarding the acquisition can be found at www.benitec.com.

About Tacere Therapeutics, Inc.:
Established in 2006, Tacere Therapeutics, Inc. is a US-based privately owned RNA interference (RNAi) Therapeutics Company that has developed therapies based on Benitec Biopharma's novel gene silencing technology ddRNAi. In 2008 Tacere Therapeutics entered into a collaboration and license agreement with Pfizer Inc. to develop and commercialise its hepatitis C virus compound TT-034. The collaboration focused on completing all necessary studies for submission of an investigational new drug application (IND), as well as clinical development and commercialisation. Pfizer Inc. invested significant resources to develop the program over a three year period. TT-034 remained a high priority pre-clinical program for Pfizer, however a major organisational restructure in 2011 led to the closure of Pfizer's UK facility where the work on TT-034 was being conducted. The hepatitis C program was subsequently put on hold and the rights passed back to Tacere in 2012.

About Benitec Biopharma Limited:
Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi, also called expressed RNAi. Benitec Biopharma is developing treatments for chronic and life-threatening human conditions such as cancer-associated pain, Hepatitis B, drug resistant lung cancer and Oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec Biopharma has licensed ddRNAi technology to other biopharmaceutical companies for applications including HIV/AIDS, hepatitis C and retinitis pigmentosa. For more information on Benitec Biopharma refer to the Company's website at www.benitec.com.

For more information please contact:

Dr. Peter French
Chief Executive Officer
Phone: +61 (02) 9555 6986
pfrench@benitec.com
www.benitec.com

RIVULET MEDIA INC. (RIVU) Stock Research Links

RIVU Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sleep Number’s Couples Pitch Has Some Fine Print Too

Updated Category News Views 75

A thermostat war in the bedroom is a lousy reason to buy the wrong mattress. Yet that is the mundane, very real problem Sleep Number is leaning into after Expert Consumers named it a leading 2026 choice for couples seeking personalized sleep comfort. The company’s argument is straightforward: two people sharing a bed should not have to share one firmness setting, or...

Continue Reading
Page Library Grant Makes a Practical Case for Access

Updated Category News Views 56

A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 7

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 25

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading
1031 Specialists Takes Tax Deferral to Public TV

Updated Category News Views 100

A tax rule most people ignore is getting a television spotlight. 1031 Specialists says it will appear on All Access with Andy Garcia, an educational series distributed to Public Television stations nationwide, to explain the 1031 exchange and its role in real estate investing. That is a sensible bit of exposure for a niche business built around a topic investors tend to...

Continue Reading
Fire-Resistant Lubricants Offer a Quiet Value Shift

Updated Category News Views 67

Hydraulic fluid is not the sort of product that gets anyone pounding the table, and that is precisely why this little industrial pocket deserves a hard look. The fire-resistant lubricants market is estimated at $2.35 billion in 2026 and projected to reach $2.83 billion by 2031, implying a 3.74% compound annual growth rate. That is not a rocket ship. It is a slow-moving,...

Continue Reading
Avenir Nears 19.99% Grid Stake After Falcon West Resource

Updated Category News Views 35

Falcon West finally put enough geological meat on the bone to make Avenir reach for its wallet. Avenir Minerals expects to buy 29,388,127 Grid Metals common shares on or about November 30, 2026, taking its non-diluted position to 19.99%. That number is not accidental. It is the usual Canadian strategic-investor ceiling before the conversation starts getting considerably...

Continue Reading
YPTC’s Florida Office Bets on Nonprofit Finance Needs

Updated Category News Views 36

A Local Flag Planted After Years of Work Florida nonprofits do not need another consultant waving a glossy slide deck around; they need clean books, grant compliance, and somebody who can tell them where the cash is going before the lights start blinking red. That is the practical opening YPTC is chasing with a Jacksonville-based Florida office, its sixteenth office...

Continue Reading
Morrison Tests Abu Dhabi as Its Next Capital Hub

Updated Category News Views 60

Abu Dhabi keeps collecting infrastructure managers the way a strong port collects ships: because the money, the policy ambition, and the projects are all converging there. Morrison’s decision to establish an office in ADGM is not some chest-thumping headline about instant deal flow. It is a practical move by a firm with nearly four decades behind it and more than US$35...

Continue Reading
NEWWAVE Turns 15 and Chases a Bigger Tech Partner Role

Updated Category News Views 97

Fifteen years is about when an outsourced engineering shop has to prove it can be more than extra hands on a keyboard. NEWWAVE’s new identity and “Trusted Technology Partner” positioning are an attempt to make that jump: from carrying out software work to helping clients decide what work ought to be done, then sticking around after launch. It is a sensible ambition,...

Continue Reading

Top 5 Most Recently Viewed Articles

Elizabeth Clement Takes the Helm at National Center for State Courts

Updated Category News Views 465

Elizabeth Clement's Appointment as NCSC President The National Center for State Courts (NCSC) has announced a significant leadership change with the appointment of Elizabeth Clement as its next president and chief executive officer. This appointment marks Clement as the organization's fifth president, succeeding Mary McQueen. Currently serving as the chief justice of the...

Continue Reading
Future Predictions on M&A Disputes and Deal Dynamics

Updated Category News Views 153

More M&A Disputes Expected in a Changing Landscape As the global merger and acquisition (M&A) market rebounds, experts are predicting an uptick in disputes stemming from the complexities of deal-making. Despite an increase in confidence about deal activities due to improved financial conditions, pressures such as geopolitical tensions and regulatory scrutiny are expected...

Continue Reading
U.S. Bancorp Shows Growth Potential and Robust Dividend Strategy

Updated Category News Views 108

U.S. Bancorp’s Strong Market Position and Outlook U.S. Bancorp (NYSE: USB) is proving its resilience in the banking industry, having recently received an In-Line rating from Evercore ISI. This rating indicates that the bank is on track to meet its medium-term performance goals, with a price target set at $49.00. During a recent virtual investor meeting, U.S. Bancorp...

Continue Reading
Galaxy Macau Unveils Fintech Station, Elevates Tourism

Updated Category News Views 56

Unveiling Macau's Fintech Beacon Today marks a significant junction in the intersection of tourism and financial technology. The Galaxy Macau and Ant Bank (Macao) unleashed their latest brainchild, the Financial Services Station, right in the bustling heart of Galaxy Macau. It's the first of its kind to grace the integrated resorts landscape, giving tourists not just a...

Continue Reading
Understanding Share Transactions by Sydbank's Managers

Updated Category News Views 152

Overview of Recent Share Transactions at Sydbank Recent transactions involving shares of Sydbank have garnered interest from various stakeholders. This activity, conducted by managers and those closely linked to them, reflects their confidence in the bank's future performance. In accordance with the Market Abuse Regulation, Sydbank is committed to maintaining transparency...

Continue Reading